"We provide medically-prescribed infusions for patients with chronic disease in a comfortable, friendly environment instead of a sterile, cold hospital."

During the past decade, Infusion Associates conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 4 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Infusion Associates" #1 sponsor was "Chiesi Farmaceutici S.p.A." with 3 trials, followed by "Amicus Therapeutics" with 2 trials sponsored, "Idorsia Pharmaceuticals Ltd." with 2 trials sponsored, "Protalix" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Infusion Associates" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials as a collaborator, "Chiesi USA, Inc." with 1 trials as a collaborator, "International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)" with 1 trials as a collaborator and "National Institutes of Health (NIH)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Infusion Associates" are "Fabry Disease" (8 trials), "Ulcerative Colitis" (2 trials), "Asthma" (1 trials), "COVID" (1 trials) and "Covid19" (1 trials). Many other conditions were trialed in "Infusion Associates" in a lesser frequency.

Most popular intervention types in "Infusion Associates" are "Drug" (13 trials), "Biological" (7 trials), "Other" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Lucerastat" (2 trials), "Pegloticase" (2 trials), "pegunigalsidase alfa" (2 trials) and "AT2221" (1 trials). Other intervention names were less common.

The vast majority of trials in "Infusion Associates" are 18 trials for "All" genders.

Currently, there are NaN active trials in "Infusion Associates". undefined are not yet recruiting, 3 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Infusion Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Infusion Associates, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".